Last reviewed · How we verify

Disease-modifying anti-rheumatic drugs

Hoffmann-La Roche · Phase 3 active Small molecule

Disease-modifying anti-rheumatic drugs is a Disease-modifying anti-rheumatic drug (DMARD) Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development for Rheumatoid arthritis, Other autoimmune inflammatory conditions (varies by specific DMARD).

Disease-modifying anti-rheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions.

Disease-modifying anti-rheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions. Used for Rheumatoid arthritis, Other autoimmune inflammatory conditions (varies by specific DMARD).

At a glance

Generic nameDisease-modifying anti-rheumatic drugs
SponsorHoffmann-La Roche
Drug classDisease-modifying anti-rheumatic drug (DMARD)
ModalitySmall molecule
Therapeutic areaImmunology / Rheumatology
PhasePhase 3

Mechanism of action

DMARDs work through various mechanisms including immunosuppression, cytokine inhibition, and modulation of T-cell and B-cell activation to reduce joint inflammation and slow radiographic progression. Unlike NSAIDs and corticosteroids that primarily manage symptoms, DMARDs alter the disease course by targeting pathogenic immune pathways. This class includes conventional synthetic DMARDs (methotrexate, sulfasalazine), biologic DMARDs (TNF inhibitors, IL-6 inhibitors, B-cell depleting agents), and targeted synthetic DMARDs (JAK inhibitors).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Disease-modifying anti-rheumatic drugs

What is Disease-modifying anti-rheumatic drugs?

Disease-modifying anti-rheumatic drugs is a Disease-modifying anti-rheumatic drug (DMARD) drug developed by Hoffmann-La Roche, indicated for Rheumatoid arthritis, Other autoimmune inflammatory conditions (varies by specific DMARD).

How does Disease-modifying anti-rheumatic drugs work?

Disease-modifying anti-rheumatic drugs (DMARDs) suppress the underlying immune-mediated inflammatory processes that drive rheumatoid arthritis and other autoimmune conditions.

What is Disease-modifying anti-rheumatic drugs used for?

Disease-modifying anti-rheumatic drugs is indicated for Rheumatoid arthritis, Other autoimmune inflammatory conditions (varies by specific DMARD).

Who makes Disease-modifying anti-rheumatic drugs?

Disease-modifying anti-rheumatic drugs is developed by Hoffmann-La Roche (see full Hoffmann-La Roche pipeline at /company/roche).

What drug class is Disease-modifying anti-rheumatic drugs in?

Disease-modifying anti-rheumatic drugs belongs to the Disease-modifying anti-rheumatic drug (DMARD) class. See all Disease-modifying anti-rheumatic drug (DMARD) drugs at /class/disease-modifying-anti-rheumatic-drug-dmard.

What development phase is Disease-modifying anti-rheumatic drugs in?

Disease-modifying anti-rheumatic drugs is in Phase 3.

What are the side effects of Disease-modifying anti-rheumatic drugs?

Common side effects of Disease-modifying anti-rheumatic drugs include Infection (including serious infections), Hepatotoxicity, Bone marrow suppression, Gastrointestinal disturbances, Immunosuppression-related malignancy risk.

Related